Announcements Trials
Browse Landscape

Status

Completed 27Recruiting 9Active not recruiting 6Terminated 4Not yet recruiting 3Withdrawn 1Unknown 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Cancer Metastatic 1

Interventions

Afatinib 3niraparib 2lenvatinib 2ibrutinib 2abemaciclib 2Trastuzumab 2Sunitinib 2Ramucirumab 2Gefitinib 2Capecitabine 2Abiraterone Acetate 23-Iodobenzylguanidine 2zenocutuzumab 1vorasidenib 1tucatinib 1trilaciclib 1trifluridine tipiracil drug combination 1tovorafenib 1talquetamab 1tafasitamab 1selpercatinib 1sacituzumab govitecan 1ripretinib 1pralsetinib 1ponatinib 1pomalidomide 1pirtobrutinib 1pertuzumab 1olaratumab 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Approved for marketing × INDUSTRY × trifluridine tipiracil drug combination × Clear all
NCT02286492 2024-09-05

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Taiho Oncology, Inc.

Approved for marketing
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡